EA202091618A1 - Композиция кетамина в виде сухого порошка для применения при лечении депрессии ингаляционным путем - Google Patents

Композиция кетамина в виде сухого порошка для применения при лечении депрессии ингаляционным путем

Info

Publication number
EA202091618A1
EA202091618A1 EA202091618A EA202091618A EA202091618A1 EA 202091618 A1 EA202091618 A1 EA 202091618A1 EA 202091618 A EA202091618 A EA 202091618A EA 202091618 A EA202091618 A EA 202091618A EA 202091618 A1 EA202091618 A1 EA 202091618A1
Authority
EA
Eurasian Patent Office
Prior art keywords
composition
depression
inhalation
treatment
dry powder
Prior art date
Application number
EA202091618A
Other languages
English (en)
Inventor
Мацей Вечорек
Эва Траткевич
Пшемыслав Перко
Original Assignee
Целон Фарма С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Целон Фарма С.А. filed Critical Целон Фарма С.А.
Publication of EA202091618A1 publication Critical patent/EA202091618A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Ингаляционная фармацевтическая композиция в виде сухого порошка, содержащая кетамин или его фармацевтически приемлемую соль для применения в способе лечения депрессии ингаляционным путем. Композиция является особенно полезной для лечения фармако-резистентной или трудноподдающейся лечению депрессии.
EA202091618A 2017-12-29 2018-09-28 Композиция кетамина в виде сухого порошка для применения при лечении депрессии ингаляционным путем EA202091618A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17461651.6A EP3505157B1 (en) 2017-12-29 2017-12-29 Dry powder ketamine composition for pulmonary administration in treatment-resistant depression
PCT/EP2018/076394 WO2019129397A1 (en) 2017-12-29 2018-09-28 Dry powder ketamine composition for use in the treatment of depression by pulmonary administration

Publications (1)

Publication Number Publication Date
EA202091618A1 true EA202091618A1 (ru) 2021-03-17

Family

ID=60915417

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202091618A EA202091618A1 (ru) 2017-12-29 2018-09-28 Композиция кетамина в виде сухого порошка для применения при лечении депрессии ингаляционным путем

Country Status (16)

Country Link
US (1) US20200337999A1 (ru)
EP (2) EP3505157B1 (ru)
JP (1) JP7315556B2 (ru)
KR (1) KR20200105857A (ru)
CN (1) CN111818912A (ru)
AU (1) AU2018395791A1 (ru)
BR (1) BR112020013282A2 (ru)
CA (1) CA3087090A1 (ru)
DK (2) DK3505157T3 (ru)
EA (1) EA202091618A1 (ru)
ES (2) ES2907692T3 (ru)
HU (2) HUE058320T2 (ru)
MX (1) MX2020006900A (ru)
PL (2) PL3505157T3 (ru)
PT (2) PT3505157T (ru)
WO (1) WO2019129397A1 (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3628313A1 (en) 2018-09-28 2020-04-01 Celon Pharma S.A. Ketamine composition for use in a method of treatment of depression by pulmonary administration

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2205018T3 (es) * 1995-02-24 2004-05-01 Stuart Weg Administracion de ketamina para destoxificacion.
GB0009469D0 (en) * 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formalities for use in inhaler devices
NZ540282A (en) * 2002-11-18 2008-06-30 Yaupon Therapeutics Inc Analgesic uses of norketamine and ketamine/norketamine prodrugs
GB0523031D0 (en) * 2005-11-11 2005-12-21 Yaupon Therapeutics Enhancement of morphine analgesia by s(-)-norketamine
JP2009530385A (ja) * 2006-03-22 2009-08-27 マウント シナイ スクール オブ メディシン うつ病の治療のためのケタミンの鼻内投与
DE102007009888A1 (de) 2007-02-28 2008-09-04 Hermann, Holger Lars, Dr. Verwendung von S-(+)-Ketamin zur Behandlung von Depressionen
GB0908129D0 (en) * 2009-05-12 2009-06-24 Innovata Ltd Composition
MX2014010939A (es) 2012-03-12 2014-11-13 Janssen Pharmaceutica Nv Esketamina para el tratamiento de la depresion refractaria al tratamiento o resistente al tratamiento.
US20140079740A1 (en) 2012-08-02 2014-03-20 ClinPharm Support GmbH Oral transmucosal adminstration forms of s-ketamine
AU2014240102A1 (en) 2013-03-15 2015-09-17 Janssen Pharmaceutica Nv Pharmaceutical composition of S-ketamine hydrochloride
ES2745024T3 (es) 2013-03-15 2020-02-27 Janssen Pharmaceutica Nv Composición farmacéutica de clorhidrato de S-ketamina
AU2014248455B2 (en) * 2013-04-01 2018-12-06 Pulmatrix Operating Company, Inc. Tiotropium dry powders
MX2017004440A (es) * 2014-10-07 2017-11-01 Lam Therapeutics Inc Una formulacion de rapamicina inhalable para el tratamiento de hipertension pulmonar.
US20160332962A1 (en) * 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
CN106562952B (zh) * 2015-10-09 2020-06-09 江阴安博生物医药有限公司 氯胺酮在治疗重性抑郁障碍中的应用
EP3628313A1 (en) * 2018-09-28 2020-04-01 Celon Pharma S.A. Ketamine composition for use in a method of treatment of depression by pulmonary administration

Also Published As

Publication number Publication date
HUE058099T2 (hu) 2022-07-28
PL3731815T3 (pl) 2022-04-11
JP7315556B2 (ja) 2023-07-26
CN111818912A (zh) 2020-10-23
DK3731815T3 (da) 2022-02-28
HUE058320T2 (hu) 2022-07-28
PT3731815T (pt) 2022-02-15
PL3505157T3 (pl) 2022-04-11
WO2019129397A1 (en) 2019-07-04
BR112020013282A2 (pt) 2020-12-01
EP3731815B1 (en) 2021-12-08
AU2018395791A1 (en) 2020-07-16
EP3731815A1 (en) 2020-11-04
MX2020006900A (es) 2020-11-09
KR20200105857A (ko) 2020-09-09
CA3087090A1 (en) 2019-07-04
EP3505157B1 (en) 2021-12-08
JP2021510682A (ja) 2021-04-30
EP3505157A1 (en) 2019-07-03
PT3505157T (pt) 2022-02-18
DK3505157T3 (da) 2022-02-28
ES2907692T3 (es) 2022-04-26
ES2907781T3 (es) 2022-04-26
US20200337999A1 (en) 2020-10-29

Similar Documents

Publication Publication Date Title
CY1120605T1 (el) Παρασκευασμα ξηρης σκονης που περιλαμβανει εναν αναστολεα φωσφοδιεστερασης
NZ746112A (en) Cyclic di-nucleotide compounds and methods of use
PH12017501046A1 (en) Azabicyclooctane derivatives as fxr agonists for use in the treatment of liver and gastrointestinal diseases
MX2019001125A (es) Inhibidores de cinasa macrociclica.
MX2016016593A (es) Nuevos derivados de aminoalquibenzotiazepina y usos de los mismos.
EP4282479A3 (en) Use of pridopidine to treat depression or anxiety
EA201591729A1 (ru) Пригодные для вдыхания агломераты частиц пористого носителя и тонкоизмельченного лекарственного средства
MX2016015434A (es) Combinaciones farmaceuticas para tratar cancer.
MX368903B (es) Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas.
MX2018011813A (es) Medicina obtenida mediante la combinacion de agonista fxr y arb.
PH12016502352A1 (en) Pharmaceutical composition
TW201613578A (en) Pharmaceutical combinations
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
CO2017001601A2 (es) Derivados de 1-acetil-4-((pirazin-2-il) amino)-1,2,3,4-tetrahydroquinolina-6 carboxamida como inhibidores de bromodominio
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
ZA202200511B (en) Ring-fused thiazolino 2-pyridones, methods for preparation thereof and their use in the treatment and/or prevention of tuberculosis
PH12018502376A1 (en) Pyridinyl derivatives, pharmaceutical compositions and uses thereof as aoc3 inhibitors
EA202091618A1 (ru) Композиция кетамина в виде сухого порошка для применения при лечении депрессии ингаляционным путем
PH12017500505A1 (en) Veliparib in combination with carboplatin and paclitaxel for the treatment of non-small cell lung cancer in smokers
EA201892842A1 (ru) Фармацевтические композиции, включающие сафинамид
BR112017009315A2 (pt) composição de pó seco farmacêutico inalável, processo para preparar uma composição de pó seco farmacêutico inalável, e, método para tratar transtornos respiratórios.
EA201890789A1 (ru) Содержащая цинеол композиция для лечения заболеваний носа
PH12018501991A1 (en) Pharmaceutical composition for use in treating fibrosis
EA201891739A1 (ru) ПРИМЕНЕНИЕ СТИМУЛЯТОРОВ sGC ДЛЯ ЛЕЧЕНИЯ НЕАЛКОГОЛЬНОГО СТЕАТОГЕПАТИТА (NASH)